share_log

Cantor Fitzgerald Reiterates Overweight on Lumos Pharma, Maintains $10 Price Target

Benzinga ·  Aug 22, 2023 09:55

Cantor Fitzgerald analyst Charles Duncan reiterates Lumos Pharma (NASDAQ:LUMO) with a Overweight and maintains $10 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment